Skip to main content

Differential treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention versus medical therapy for acute coronary syndromes: exploration of methods.

Publication ,  Journal Article
Pieper, KS; Tsiatis, AA; Davidian, M; Hasselblad, V; Kleiman, NS; Boersma, E; Chang, W-C; Griffin, J; Armstrong, PW; Califf, RM; Harrington, RA
Published in: Circulation
February 10, 2004

BACKGROUND: Although many believe that platelet glycoprotein IIb/IIIa inhibitors should be used only in acute coronary syndrome patients undergoing percutaneous coronary intervention, supporting data from randomized clinical trials are tenuous. The assumption that these agents are useful only in conjunction with percutaneous coronary intervention is based primarily on inappropriate subgroup analyses performed across the glycoprotein IIb/IIIa inhibitor trials. METHODS AND RESULTS: We describe the problems with these analytical techniques and demonstrate that different approaches to the question can result in opposing answers. CONCLUSIONS: Clinical-practice decisions and practice guidelines should be based on overall trial results and not analyses of post-randomization subgroups.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Circulation

DOI

EISSN

1524-4539

Publication Date

February 10, 2004

Volume

109

Issue

5

Start / End Page

641 / 646

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Syndrome
  • Research Design
  • Randomized Controlled Trials as Topic
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Patient Selection
  • Myocardial Revascularization
  • Middle Aged
  • Male
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Pieper, K. S., Tsiatis, A. A., Davidian, M., Hasselblad, V., Kleiman, N. S., Boersma, E., … Harrington, R. A. (2004). Differential treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention versus medical therapy for acute coronary syndromes: exploration of methods. Circulation, 109(5), 641–646. https://doi.org/10.1161/01.CIR.0000112570.97220.89
Pieper, Karen S., Anastasios A. Tsiatis, Marie Davidian, Vic Hasselblad, Neal S. Kleiman, Eric Boersma, Wei-Ching Chang, et al. “Differential treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention versus medical therapy for acute coronary syndromes: exploration of methods.Circulation 109, no. 5 (February 10, 2004): 641–46. https://doi.org/10.1161/01.CIR.0000112570.97220.89.
Pieper, Karen S., et al. “Differential treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention versus medical therapy for acute coronary syndromes: exploration of methods.Circulation, vol. 109, no. 5, Feb. 2004, pp. 641–46. Pubmed, doi:10.1161/01.CIR.0000112570.97220.89.
Pieper KS, Tsiatis AA, Davidian M, Hasselblad V, Kleiman NS, Boersma E, Chang W-C, Griffin J, Armstrong PW, Califf RM, Harrington RA. Differential treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention versus medical therapy for acute coronary syndromes: exploration of methods. Circulation. 2004 Feb 10;109(5):641–646.

Published In

Circulation

DOI

EISSN

1524-4539

Publication Date

February 10, 2004

Volume

109

Issue

5

Start / End Page

641 / 646

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Syndrome
  • Research Design
  • Randomized Controlled Trials as Topic
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Patient Selection
  • Myocardial Revascularization
  • Middle Aged
  • Male
  • Humans